028300.KQ
HLB Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 32,800.00
−1.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 97.5B | 83.9B | 68.1B | 42.9B | 179.7B |
| Cost of Revenue | 60.1B | 59.3B | 56.1B | 44.0B | 128.5B |
| Gross Profit | 37.4B | 24.9B | 12.1B | (1.1B) | 51.3B |
| Operating Expenses | |||||
| R&D Expense | 55.9B | 59.9B | 41.2B | 49.1B | 43.9B |
| SG&A Expense | 50.7B | 29.6B | 38.7B | 33.0B | 22.7B |
| General & Admin Expense | 4.7B | 5.7B | 9.6B | 7.3B | 6.9B |
| Selling & Marketing Expense | 22.0B | 23.9B | 29.1B | 25.7B | 15.8B |
| Other Expenses | 24.0B | 34.6B | 50.6B | 42.0B | (25.9M) |
| Total Operating Expenses | 130.6B | 124.2B | 130.6B | 124.1B | 125.9B |
| Cost and Expenses | 190.7B | 183.5B | 186.6B | 167.9B | 254.4B |
| Operating Income (EBIT) | (93.2B) | (99.3B) | (118.5B) | (125.0B) | (74.7B) |
| Non-Operating | |||||
| Interest Income | 5.1B | 2.6B | 3.2B | 6.7B | 1.6B |
| Interest Expense | 24.9B | 12.4B | 10.7B | 10.6B | 11.7B |
| Net Interest Income | (19.7B) | (9.8B) | (7.5B) | (3.9B) | (10.1B) |
| Other Non-Op Income/Expense | (138.6B) | (141.2B) | 9.3B | (87.8B) | (13.7B) |
| Non-Operating Income (excl Interest) | 57.4B | — | (20.0B) | 54.2B | 2.1B |
| EBT (Pre-Tax Income) | (231.8B) | (240.5B) | (109.2B) | (212.8B) | (79.0B) |
| Income Tax Expense | (4.8B) | (5.1B) | (1.2B) | (10.5B) | 10.2B |
| Bottom Line | |||||
| Net Income | (213.5B) | (220.5B) | (92.0B) | (189.1B) | (78.2B) |
| Earnings from Cont. Ops | (227.0B) | (235.4B) | (108.0B) | (206.0B) | (89.2B) |
| Earnings from Discont. Ops | — | — | — | 23.0B | — |
| Bottom Line Net Income | (213.5B) | (220.5B) | (92.0B) | (189.1B) | (78.2B) |
| Per Share | |||||
| Basic EPS | (₩1,615) | (₩1,680) | (₩704) | (₩1,560) | (₩694) |
| Diluted EPS | (₩1,615) | (₩1,680) | (₩704) | (₩1,560) | (₩694) |
| Revenue Per Share | ₩733 | ₩636 | ₩521 | ₩354 | ₩1,596 |
| Shares | |||||
| Basic Shares Outstanding | 132.9M | 131.9M | 130.7M | 121.2M | 112.6M |
| Diluted Shares Outstanding | 132.9M | 131.9M | 130.7M | 121.2M | 112.6M |
| Profitability Metrics | |||||
| EBITDA | (91.4B) | (94.0B) | (92.3B) | (172.3B) | (60.4B) |
| D&A | 6.2B | 5.4B | 6.2B | 9.7B | 16.3B |
| EBIT | (97.6B) | (99.3B) | (98.5B) | (179.2B) | (76.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026